CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities
Net income (loss)	$ 118,191	$ 288,576
Adjustments to reconcile net income to net cash provided by operating activities:
Deferred income taxes	(1,115)	29,258
Amortization of capitalized fees and depreciation of property and equipment	10,437	10,447
Amortization of acquired intangible assets	15,274	1,511
Inventory fair value step-up adjustment included in cost of products sold	19,179	2,743
Stock-based compensation	4,560	6,021
Amortization of debt discount and issuance costs	1,549	1,491
Changes in fair values of equity method investments, net	(67,886)	44,475
Changes in fair values of other equity and long-term investments, net	4,887	21,973
Loss on extinguishment of debt	0	20,662
Net gain on sale of TRC	0	(266,696)
Accrued interest income added to long-term investments	(1,482)	0
Other non-cash items	(770)	2,026
Changes in operating assets and liabilities:
Accounts receivable	(1,351)	(867)
Receivables from collaboration arrangement	(2,341)	2,385
Inventory	(3,797)	350
Prepaid expenses	14,830	277
Other assets	1,795	(2,932)
Accounts payable	844	958
Accrued personnel-related expenses and other accrued liabilities	(1,072)	(1,709)
Accrued interest payable	(3,526)	(1,926)
Income tax payable	148	33,804
Deferred revenue	(546)	0
Net cash provided by operating activities	107,808	192,827
Cash flows from investing activities
Purchases of equity method investments	0	(45,000)
Purchases of trading securities	(60,132)	0
Purchases of equity and long-term investments	(1,218)	(13,725)
Purchases of equity investments managed by ISP Fund LP	(24,914)	(92,951)
Sales of equity investments managed by ISP Fund LP	39,642	24,281
Purchase and sales of other investments managed by ISP Fund LP, net	(14,728)	(41,330)
Purchases of property and equipment	(260)	(33)
Proceeds from sale of ownership interest in TRC, net	0	248,191
Cash acquired through the consolidation of Entasis	0	23,070
Cash paid for the acquisition of La Jolla Pharmaceutical Company, net of cash acquired	0	(150,459)
Net cash used in investing activities	(61,610)	(47,956)
Cash flows from financing activities
Distributions to noncontrolling interests	0	(69,811)
Purchase of Entasis minority interest	0	(42,395)
Repurchase of common stock	(61,092)	0
Repurchase of shares to satisfy tax withholding	(65)	(71)
Proceeds from issuances of common stock, net	111	342
Payment for repurchase of convertible subordinated notes due 2023	(96,204)	(165,131)
Purchases of capped call options associated with convertible senior notes due 2028	0	(21,037)
Proceeds from issuance of convertible senior notes due 2028, net of issuance costs	0	252,536
Net cash used in financing activities	(157,250)	(45,567)
Net (decrease) increase in cash and cash equivalents	(111,052)	99,304
Cash and cash equivalents at beginning of period	291,049	201,525
Cash and cash equivalents at end of period	179,997	300,829
Supplemental Disclosure of Cash Flow Information:
Cash paid for interest	11,381	11,736
Cash paid for income taxes	0	3,859
Supplemental Disclosure of Non-cash Investing and Financing Activities:
Adoption of ASU 2020-06	0	28,123
Right-of-use asset obtained through the consolidation of Entasis Therapeutics Holdings, Inc.	463	3,323
Reconciliation of Cash, Cash Equivalents and Restricted Cash:
Cash and cash equivalents	179,997	300,789
Restricted cash, included in "Other assets"	0	40
Total cash, cash equivalents and restricted cash at end of period shown in the condensed consolidated statements of cash flows	$ 179,997	$ 300,829